美德纳Moderna Inc. (MRNA) 2021年年度报告「NASDAQ」.pdf

1、2021 annual reportAll figures as of December 31,2021,except for development programs figures,which are as of March 8,2022.Growth in number of development programs also reflects an increase due to classification of programs fordifferent aged populations for RSV and COVID-19(e.g.,children andadolescen

2、ts)as separate programs.20202021132520202021244420202021$17.6B$5.2B2010 founding year2,700+team members(up from 1,300 last year)Cambridge,MAheadquarters47%women in our workforce5therapeutic areas:Infectious DiseasesImmuno-OncologyRare DiseasesCardiovascular DiseasesAutoimmune Diseases7years in a row

3、 as a Science top employerModerna by the numbers807Mdoses of Modernas COVID-19 vaccine shipped in 2021development programsdevelopment candidates in active clinical trialscash,cash equivalents,and investmentsFranceGermanySwitzerlandItalyUnited KingdomSpainUnited StatesCanada12 COUNTRIES ACROSS NORTH

4、AMERICA,EUROPE AND ASIA WHERE MODERNA EMPLOYEES LIVE AND WORKSouth Korea AustraliaJapanPolandTable of contents05A letter from our CEO20 Pipeline24 Building our team,integratingourMindsets28 Responsibility30 Leadership31 Awards and recognition32 Financials3moderna 2021annual report|Each year,I look f

5、orward to sending my letter to shareholders the first week of January.It is an important time to reflect on the past year and look ahead to our priorities for the months and years to come.Although only two short months have passed since I shared my annual letter with all of you on January 4,our team

6、 has continued to operate at“Moderna speed”to make significant advancements toward our mission.I am pleased to provide a few updates:Spikevax approval:Our COVID-19 vaccine has received approval by regulators in more than 70 countries,including full Biologics License Application approval for Spikevax